77,141 Shares in AngioDynamics, Inc. $ANGO Bought by Stonepine Capital Management LLC

Stonepine Capital Management LLC acquired a new stake in shares of AngioDynamics, Inc. (NASDAQ:ANGO) in the second quarter, HoldingsChannel reports. The fund acquired 77,141 shares of the medical instruments supplier’s stock, valued at approximately $765,000.

Several other hedge funds also recently bought and sold shares of the company. Legal & General Group Plc raised its stake in shares of AngioDynamics by 279.5% during the 2nd quarter. Legal & General Group Plc now owns 12,353 shares of the medical instruments supplier’s stock worth $123,000 after purchasing an additional 9,098 shares in the last quarter. Los Angeles Capital Management LLC acquired a new position in AngioDynamics in the second quarter worth approximately $139,000. Fox Run Management L.L.C. acquired a new position in AngioDynamics in the first quarter worth approximately $145,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management raised its position in AngioDynamics by 13.5% during the second quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 16,747 shares of the medical instruments supplier’s stock valued at $166,000 after acquiring an additional 1,989 shares in the last quarter. Finally, Integrated Quantitative Investments LLC acquired a new stake in AngioDynamics in the second quarter valued at approximately $241,000. 89.43% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have recently commented on ANGO shares. Weiss Ratings restated a “sell (d-)” rating on shares of AngioDynamics in a research note on Wednesday, October 8th. Canaccord Genuity Group upped their price objective on shares of AngioDynamics from $17.00 to $18.00 and gave the stock a “buy” rating in a report on Friday, October 3rd. Finally, Wall Street Zen raised shares of AngioDynamics from a “hold” rating to a “buy” rating in a research report on Friday, November 28th. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $19.33.

Insider Activity

In other AngioDynamics news, CEO James C. Clemmer purchased 10,000 shares of the company’s stock in a transaction on Thursday, October 9th. The shares were bought at an average cost of $11.15 per share, with a total value of $111,500.00. Following the transaction, the chief executive officer directly owned 882,529 shares in the company, valued at approximately $9,840,198.35. This represents a 1.15% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Lawrence T. Weiss purchased 10,000 shares of the business’s stock in a transaction dated Tuesday, October 21st. The shares were acquired at an average price of $11.81 per share, with a total value of $118,100.00. Following the completion of the acquisition, the senior vice president owned 93,597 shares of the company’s stock, valued at approximately $1,105,380.57. The trade was a 11.96% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have purchased a total of 20,890 shares of company stock valued at $239,532 in the last three months. 6.00% of the stock is owned by insiders.

AngioDynamics Trading Up 0.9%

Shares of AngioDynamics stock opened at $13.49 on Thursday. The firm has a fifty day simple moving average of $11.88 and a 200-day simple moving average of $10.52. The stock has a market capitalization of $555.79 million, a price-to-earnings ratio of -17.29 and a beta of 0.49. AngioDynamics, Inc. has a 1-year low of $6.92 and a 1-year high of $13.63.

AngioDynamics (NASDAQ:ANGO) last announced its earnings results on Thursday, October 2nd. The medical instruments supplier reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.12) by $0.02. AngioDynamics had a negative net margin of 10.67% and a negative return on equity of 3.16%. The firm had revenue of $75.71 million for the quarter, compared to the consensus estimate of $72.69 million. During the same quarter last year, the firm posted ($0.11) EPS. The business’s quarterly revenue was up 12.1% on a year-over-year basis. AngioDynamics has set its FY 2026 guidance at -0.330–0.230 EPS. As a group, research analysts predict that AngioDynamics, Inc. will post -0.37 earnings per share for the current year.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.